B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.
Johannes GrissWolfgang Michael BauerChristine WagnerMartin SimonMinyi ChenKatharina Grabmeier-PfistershammerMargarita Maurer-GranofszkyFlorian RokaThomas PenzChristoph BockGao ZhangMeenhard HerlynKatharina GlatzHeinz LaubliKirsten D MertzPeter PetzelbauerThomas WiesnerMarkus HartlWinfried F PicklRajasekharan SomasundaramPeter SteinbergerStephan N WagnerPublished in: Nature communications (2019)
Tumor associated inflammation predicts response to immune checkpoint blockade in human melanoma. Current theories on regulation of inflammation center on anti-tumor T cell responses. Here we show that tumor associated B cells are vital to melanoma associated inflammation. Human B cells express pro- and anti-inflammatory factors and differentiate into plasmablast-like cells when exposed to autologous melanoma secretomes in vitro. This plasmablast-like phenotype can be reconciled in human melanomas where plasmablast-like cells also express T cell-recruiting chemokines CCL3, CCL4, CCL5. Depletion of B cells in melanoma patients by anti-CD20 immunotherapy decreases tumor associated inflammation and CD8+ T cell numbers. Plasmablast-like cells also increase PD-1+ T cell activation through anti-PD-1 blockade in vitro and their frequency in pretherapy melanomas predicts response and survival to immune checkpoint blockade. Tumor associated B cells therefore orchestrate and sustain melanoma inflammation and may represent a predictor for survival and response to immune checkpoint blockade therapy.